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Introduction: Desvenlafaxine, the active metabolite of venlafaxine, is a serotonin norepinephrine 
reuptake inhibitor (SNRI) recently approved for the treatment of major depressive disorder. It is 
one of only three medications in this class available in the United States.
Aims: The objective of this article is to review the published evidence for the safety and 
efficacy of desvenlafaxine, and to compare it to other antidepressants to delineate its role in 
the treatment of depression.
Evidence review: At the recommended dose of 50 mg per day the rate of response and remission 
was similar to other SNRIs, as was the adverse effect profile. The rate of discontinuation was 
no greater than placebo, and a discontinuation syndrome was not observed at this dose. Higher 
doses were not associated with greater efficacy, but they did lead to more side effects, and the 
use of a taper prior to discontinuation. The most common side effects reported were insomnia, 
somnolence, dizziness, and nausea. Some subjects experienced clinically significant blood 
pressure elevation.
Place in therapy: Like duloxetine, desvenlafaxine inhibits the reuptake of both norepinephrine 
and serotonin at the starting dose. Dual reuptake inhibitors have been shown to have small but 
statistically significantly greater rates of response and remission compared to selective serotonin 
reuptake inhibitors, and they have also shown early promise in the treatment of neuropathic 
pain. Desvenlafaxine may prove to be a valuable treatment option by expanding the limited 
number of available dual reuptake inhibitors.
Keywords: desvenlafaxine, depression, reuptake inhibitors, norepinephrine, serotonin
Core evidence outcomes summary for desvenlafaxine in depression
Outcome measure Evidence Implications/Comments
Disease-oriented evidence
Significant reduction in depression 
symptoms (HAMD17)
Substantial Desvenlafaxine effectively treats 
depression at 50–100 mg per day.
Discontinuation due to adverse events 
in the 50 mg group was similar to 
placebo
Substantial Desvenlafaxine 50–100 mg per day is safe 
and well-tolerated.
No serious symptoms associated with 
discontinuation of 50 mg dose (DESS)
Clear Desvenlafaxine 50 mg can be 
discontinued without a taper.
reduction in various indices of chronic 
pain (vAS-Pi)
Moderate Desvenlafaxine may be useful in treating 
chronic pain, however the clinical trials were 
not designed to measure efficacy for pain.
Patient-oriented evidence
reduction in disability indices (SDS) Clear Desvenlafaxine produced a significant 
reduction in disability due to depression.
improvement in psychological 
well-being indices (wHO-5)
Clear Desvenlafaxine significantly improved 
psychological well-being.
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Scope, aims, and objectives
Desvenlafaxine (DVS) is the most recently approved 
medication for the treatment of major depressive disorder. 
DVS is chemically unrelated to tricyclic, tetracyclic, or other 
available antidepressants (with the exception of venlafaxine), 
and is classified as a dual-acting serotonin (5-HT) and 
norepinephrine (NE) reuptake inhibitor (SNRI). Nonclinical 
studies have demonstrated that it inhibits the neuronal uptake 
of both 5-HT and NE and, to a lesser degree, dopamine. 
It does not have any monoamine oxidase inhibitory activity, 
and it shows virtually no affinity for rat brain muscarinic cho-
linergic, H1-histaminergic, or alpha-1 adrenergic receptors.
The objective of this article is to review the published 
evidence for the safety and efficacy of DVS that led to its 
approval by the US Food and Drug Administration (FDA). 
Additionally, DVS is compared to other antidepressants 
in order to delineate the advantages and disadvantages 
of this drug, and its appropriate place in the treatment of 
depression.
Methods
The English language medical literature was searched in 
August 2008 using the following databases. Search terms 
used were “desvenlafaxine OR DVS.” Nonhuman and 
in vitro studies were excluded from the search. Results are 
shown in Table 1.
•	 PubMed, http://www.ncbi.nlm.nih.gov/sites/entrez
•	 The Cochrane Library, http://www.mrw.interscience.
wiley.com/cochrane
•	 EMBASE, http://www.datastarweb.com/
•	 BIOSIS, http://www.datastarweb.com/
•	 National Institute for Health and Clinical Evidence 
(NICE), http://www.nice.org.uk/
•	 York University Centre for Reviews and Dissemination 
databases, http://www.crd.york.ac.uk/crdweb
Disease overview
Major depressive disorder (MDD) is diagnosed based on the 
presence of a constellation of signs and symptoms that are 
characteristic of the illness. This type of phenomenological 
definition differs significantly from etiological diagnoses 
in which a disease is diagnosed by the presence of a 
causative agent (ie, mycobacteria in tuberculosis) or specific 
pathophysiological abnormality (ie, plaques and tangles 
in Alzheimer’s disease). Nevertheless, using standardized 
criteria, the reliability of the diagnosis of major depressive 
disorder is high.1 Like most psychiatric disorders, the etiology 
and pathophysiology of major depressive disorder is not 
well understood, however, we do know that it is highly 
prevalent, is often disabling, and responds to both somatic 
and psychotherapeutic treatment.
The essential feature of a major depressive episode is 
a period of at least two weeks during which there is either 
depressed mood or the loss of interest or pleasure in nearly 
all activities.2 In children and adolescents, the mood may be 
irritable rather than sad. The individual must also experience 
at least four additional symptoms drawn from a list that 
includes changes in appetite, weight, sleep, or psychomotor 
activity; decreased energy; feelings of worthlessness or 
guilt; difficulty thinking, concentrating, or making decisions; 
and recurrent thoughts of death, suicidal ideation, plans, 
or attempts. A symptom must either be newly present or 
must have clearly worsened compared with the individual’s 
pre-episode status.
The symptoms must persist for most of the day, nearly 
every day, for at least two consecutive weeks. The episode 
must be accompanied by clinically significant distress or 
impairment in social, occupational, or other important areas 
of functioning. Diagnostic criteria are listed in Table 2.
For some individuals with milder episodes, functioning 
may appear to be normal but requires markedly increased 
effort. The mood in a major depressive episode is often 
described by the person as depressed, sad, hopeless, 
discouraged, or “down in the dumps”. In some cases, sadness 
may be denied at first, but may subsequently be elicited by 
interview (eg, by pointing out that the individual looks as if he 
or she is about to cry). Some individuals complain of feeling 
“flat”, having no feelings, or feeling anxious. At times, the 
presence of a depressed mood can be inferred from the 
Table 1 Evidence base included in the review
Category Number of records
Full papers Abstracts
initial search 20 6
  records excluded 14 2
  records included 6 4
Level 1 clinical evidence  
(systematic review, meta-analysis)
0 0
Level 2 clinical evidence (rCT) 6 4
Level 3 clinical evidence
  Trials other than rCT 0 0
  Case studies 0 0
Economic evidence 0 0
Total records included 6 4
Abbreviation: rCT, randomized controlled trials.
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person’s facial expression and demeanor. Some patients 
emphasize somatic complaints (eg, bodily aches and pains) 
rather than reporting feelings of sadness. Many individuals 
report or exhibit increased irritability (eg, persistent anger, 
a tendency to respond to events with angry outbursts or 
blaming others, or an exaggerated sense of frustration over 
minor matters).
Epidemiology
MDD is a leading cause of disability due to its high prevalence 
and the severity of functional impairment associated with its 
symptoms.3 Estimates of the general population prevalence 
of mental disorders in the United States have been most 
extensively measured using structured lay interviews. The 
first such instrument was the Diagnostic Interview Schedule,4 
which was developed for use in the Epidemiologic Catchment 
Area (ECA) study.5 Using the Diagnostic and Statistical 
Manual of Mental Disorders, Third Edition (DSM-III) 
criteria,6 MDD prevalence estimates in the ECA sites were 
3.0% to 5.9% for lifetime and 1.7% to 3.4% for 12-month 
estimates.7
A decade later a second nationally representative survey 
using a method similar to the ECA was carried out called 
the National Comorbidity Survey (NCS).8 Unlike the ECA, 
the NCS used memory priming strategies and respondent 
motivation techniques which resulted in prevalence estimates 
that were substantially higher: 14.9% for lifetime and 8.6% 
for 12-month estimates.9
Since the NCS was conducted there has been an increasing 
awareness of depression. A number of large national 
programs to promote knowledge about depression have 
been launched,10,11 and there has been a large increase in the 
number of Americans who take antidepressant medications.12 
Some believed that depression was being overdiagnosed, 
and that the prevalence of MDD had been overestimated in 
the ECA and NCS studies because of the possibility that a 
substantial proportion of respondents classified as cases had 
clinically insignificant manifestations of the disease despite 
meeting the symptom criteria.13 This concern, that depression 
was being overdiagnosed, led to changes in the diagnostic 
criteria in the fourth edition of the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV). Symptoms used 
to make the diagnosis were required to cause clinically 
significant distress or impairment in social, occupational, or 
some other important area of functioning.2
The National Comorbidity Survey Replication (NCS-R), 
a new national survey of mental disorders, was conducted in 
2001–2002, in which DSM-IV criteria were used, including 
the requirement of clinical significance.14 In this face-to-face 
study of 9,000 adults, age 18 years or older, results similar 
to the NCS were found. The prevalence of depression for 
lifetime was 16.2%, and for 12-month it was 6.6%. Using the 
clinical significance classification, the severity of symptoms 
was evaluated: 10.4% of the cases were mild, 38.6% 
moderate, 38.0% severe, and 12.9% very severe.
Disease burden
The burden of disease can be measured in a number of 
different ways. One of the simpler measures is the mortality 
associated with the illness. From a clinical standpoint, the 
mortality associated with depression is distressingly high. For 
example, a meta-analysis of 23 papers from nine countries 
found that depressed persons had a suicide risk 20 times that 
of the general population.15
Table 2 Diagnostic criteria for major depressive disorder. Copyright © 1994.  American Psychiatric Association. Diagnostic and statistical 
manual of mental disorders. 4th edition. washington, DC:  American Psychiatric Association, 1994
Presence of five out of the following symptoms, including depressed mood:
Depressed mood most of the day, nearly every day, as indicated by either subjective report (eg, feels sad or empty) or observation made by others 
(eg, appears tearful). (in children and adolescents, this may be characterized as an irritable mood).
Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day.
Significant weight loss when not dieting or weight gain (eg, a change of more than 5 kg of body weight in a month), or decrease or increase in appetite 
nearly every day.
insomnia or hypersomnia nearly every day.
Psychomotor agitation or retardation nearly every day.
Fatigue or loss of energy nearly every day.
Feelings of worthlessness or excessive or inappropriate guilt nearly every day.
Diminished ability to think or concentrate, or indecisiveness, nearly every day.
Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for 
committing suicide.
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From an epidemiologic point of view however, death is 
a relatively rare outcome of depression. In the World Health 
Organization estimates of mortality and burden of disease 
for 2002, depression, as a specific illness, was not one of the 
top 15 causes of global mortality.16 Self-inflicted injuries, 
which include suicide from all mental illnesses and all other 
causes, ranked 14. The top three were ischemic heart disease, 
cerebrovascular disease, and lower respiratory infections.
Another way of measuring the burden of a disease is by 
measuring the disability that it causes. Conditions that are the 
chief causes of disability are generally very different from 
leading causes of death, and have been mostly ignored in 
debates about public health priorities. Because depression 
does not kill those who suffer from it, and because it is a 
chronic illness with serious symptoms, the burden, as mea-
sured by years of life lived with a disability (YLD), is high. 
The Global Burden of Disease Study17 found that unipolar 
major depression was the leading cause of worldwide YLD 
in 1990, accounting for 10.7% of the total.18 The second 
leading cause, iron-deficiency anemia, was responsible for 
4.7% of YLD, less than half of that caused by depression. 
The authors note that the massive but largely unrecognized 
burden of mental illness is clearly evident in this study, with 
neuropsychiatric disorders filling five of the top ten causes 
of disability. These included unipolar major depression, 
alcohol use, bipolar disorder, schizophrenia, and obsessive 
compulsive disorder.
Disability adjusted life years (DALYs) is a measurement 
that blends mortality and disability in order to provide a 
more comprehensive representation of the burden of an 
illness.19 DALYs are calculated by starting with years of 
life lost due to an illness, eg, mortality. An adjustment is 
made for the value of time lived at different ages reflecting 
the dependence of the young and the elderly on adults. The 
time lived with a disability is made comparable with the 
time lost due to premature mortality by assigning a severity 
weight between 0 and 1, in which a year with no disability 
is weighted 0, and a year lost due to premature mortality is 
weighted 1. For example, a Class 1 disability, which has a 
weight of 0.096, is represented by limited ability to perform 
at least one activity in one of the following areas: recreation, 
education, procreation, or occupation. By contrast, a Class 4 
disability, which has a weight of 0.6, is represented by limited 
ability to perform most activities in all of the following areas: 
recreation, education, procreation, and occupation.
In 2002 unipolar depressive disorder ranked fourth as 
a leading cause of DALYs globally.16 The top three causes 
were perinatal conditions, lower respiratory infections, and 
HIV/AIDS. Projections looking forward to 2030 predict 
depression rising to the second leading cause of DALYs, 
with HIV/AIDS as the leading cause, and ischemic heart 
disease rising to third. Overall, despite the relatively low 
mortality associated with depression, it is a serious illness 
that is one of the largest contributors to the global burden 
of disease.
Current therapy options
Treatment guidelines
The American Psychiatric Association (APA) guideline 
for the treatment of MDD provides evidence-based 
recommendations for the assessment and treatment of 
adults with depression.20 Treatment may be divided into 
four phases corresponding to the natural history of MDD: 
acute, continuation, maintenance, and discontinuation. 
The goal during the acute phase is remission of symptoms. 
Other phases are centered on maintenance of gains and the 
prevention of relapse.
The guidelines extensively discuss the use of antidepressant 
medication in the treatment of MDD, but also note that in 
addition to pharmacotherapy, psychiatric management should 
incorporate a broad array of interventions that include a 
diagnostic evaluation, an evaluation of the safety of the 
patient and others, an evaluation of the level of functional 
impairment, determination of the best treatment setting, 
establishing and maintaining a therapeutic alliance, providing 
education to patients and families, enhancing treatment 
adherence, and working with patients to address early signs 
of relapse.
The selection of a medication is influenced by a number 
of factors including the nature and severity of a patient’s 
symptoms, as well as the patient’s preference. Antidepressant 
medications that have been shown to be effective are 
listed in Table 3. The guidelines conclude that the overall 
effectiveness of antidepressant medications is comparable 
between classes and within classes of medications. Therefore, 
the initial selection of an antidepressant should be based on 
past response, family history of response, anticipated side 
effects, and cost. Implementation of pharmacotherapy may 
require titration from a low starting dose to the full thera-
peutic dose at a rate dependent on patient tolerability and 
co-morbid medical conditions. Patients who have started an 
antidepressant need to be closely monitored for worsening 
of symptoms and any adverse effects which may arise.
The APA guidelines provide a broad discussion of 
interventions that are considered to be well-supported by 
clinical evidence. More specific treatment guidance can 
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be obtained from the Texas Medication Algorithm Project 
(TMAP), which provides step-by-step recommendations for 
medication selection. An evaluation of the performance of 
the algorithm demonstrated superior outcomes compared 
to treatment as usual for patents with moderate to severe 
depression.21
TMAP treatment consists of a total of seven stages for 
nonpsychotic MDD and five for psychotic MDD. Each stage 
represents management of increasing levels of treatment 
resistance. For nonpsychotic MDD, Stage 1 involves monotherapy 
that can include a selective serotonin re-uptake inhibitor (SSRI), 
bupropion extended release (ER), nefazodone, a serotonin 
Table 3 FDA-approved medications for the treatment of major depressive disorder
Starting dose (mg/day) Target daily dose (mg/day)
SSris
 citalopram (Celexa®) 20 20–60
 fluoxetine (Prozac®) 20 20–60
 paroxetine (Paxil®, Paxil Cr®, Pexeva®) 20 20–60
 sertraline (Zoloft®) 50 50–200
 escitalopram (Lexapro®) 10 10–30
Tricyclics and tertracyclics
 amitriptyline (Elavil®, Endep®) 25–50 100–300
 clomipramine (Anafranil®) 25 100–250
 doxepin (Adapin®, Sinequan®) 25–50 100–300
 imipramine (Tofranil®) 25–50 100–300
 trimipramine (Surmontil®) 25–50 100–300
 desipramine (Norpramin®) 25–50 100–300
 nortriptyline (Pamelor®, Aventyl®) 25 50–200
 protriptyline (vivactil®) 10 15–60
 amoxapine (Asendin®) 50 100–400
 maprotiline (Ludiomil®) 50 100–225
Dopamine–norepinephrine  
reuptake inhibitors
 Bupropion (wellbutrin®) 150 150–300
  Bupropion, sustained release  
(wellbutrin Sr®, Budeprion Sr®)
150 150–300
  bupropion extended release  
(wellbutrin XL®, Budeprion XL®)
150 150–300
Serotonin–norepinephrine  
reuptake inhibitors
 duloxetine (Cymbalta®) 30 60
 venlafaxine Xr (Effexor Xr®) 37.5 75–225
 desvenlafaxine Er (Pristiq®) 50 50–100
Serotonin modulators
 nefazadone (Serzone®) 50 150–300
 trazadone (Desyrel®) 50 50–300
Norepinephrine–serotonin modulators
 mirtazapine (remeron®) 15 45
Monoamine oxidase inhibitors
 tranylcypromine (Parnate®) 10 30–60
 phenelzine (Nardil®) 15 15–90
 selegeline transdermal (Emsam®) 6 9–12
 isocarboxazid (Marplan®) 20 40–60
Abbreviations: Cr, controlled release; FDA, US Food and Drug Administration; SSris, selective serotonin reuptake inhibitors; Xr, extended release.
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norepinephrine reuptake inhibitor (SNRI), or mirtazapine. 
DVS was not included in the algorithm because it had not been 
released at the time the algorithm was developed.
Partial response at any stage leads to a recommendation 
of augmentation. Medications shown to be efficacious when 
used to augment antidepressant treatment include lithium, 
thyroid hormone, buspirone, and bupropion. In the absence 
of a response, or failure of an augmentation strategy, a switch 
is recommended to either an antidepressant in the same class 
or in a different class (Stage 2). It is also acceptable to switch 
immediately to another antidepressant in the same or different 
class after partial response with initial monotherapy.
Stage 3 involves the use of an older generation 
antidepressant, either a tricyclic antidepressant (TCA) or a 
monoamine oxidase inhibitor (MAOI). Because tricyclic 
antidepressants can be lethal in overdose,22 and the safe use of 
MAOIs involves adherence to a low-tyramine diet,23 these two 
classes are usually not used as first line agents. If either a TCA 
or MAOI is ineffective in bringing about remission, lithium 
augmentation is recommended (Stage 4) if it has not been tried 
previously. Stage 5 involves combinations of antidepressants, 
and Stage 6 is electroconvulsive therapy (ECT). If ECT is 
ineffective or contraindicated, use of medications which have 
not been approved for use in the treatment of MDD can be tried 
(Stage 7). These include, but are not limited to lamotrigine, 
fluvoxamine, and olanzapine.
Psychotic major depression (PMD) is a subtype of MDD 
that is defined by the presence of delusions or hallucinations 
occurring in the context of a severe depressive episode 
(DSM-IV). PMD is associated with greater illness severity, 
impairment, comorbidity, and mortality when compared 
with MDD. Furthermore, PMD patients tend to have higher 
rates of illness chronicity, relapse, and hospitalization. 
Typically these patients require adjunctive treatment with 
antipsychotic medication or ECT.24 According to the 
Texas Medication Algorithm, the first line of treatment for 
depression with psychotic features includes a combination of 
an antidepressant with an antipsychotic medication (Stage 1). 
If only a partial response is achieved a TCA should be tried 
(or a non-TCA antidepressant if a TCA was used in Stage 1). 
If remission is still not achieved, ECT is indicated, where 
appropriate. If this is unsuccessful, lithium augmentation 
should be tried, and finally combinations of more than one 
antidepressant with an antipsychotic medication.
Comparator drugs
Before 1980, antidepressant treatment consisted primarily of 
the TCAs and the MAOIs, both of which affect the activity 
of multiple monoamine neurotransmitters. These medications 
also interacted with a number of unrelated receptors which led 
to a substantial burden of side effects. The TCAs antagonize 
muscarinic cholinergic, H1-histaminic, and alpha-adrenergic 
receptors, causing constipation, urinary retention, dry mouth, 
sedation, weight gain, and postural hypotension. In addition 
to these side effects, the monoamine oxidase inhibitors have 
the added risk of potentially severe hypertensive crises due 
to the effects of dietary tyramine, which requires dietary 
restrictions.25
The introduction of the SSRIs marked the beginning of an 
era of greater selectivity. This class of medication includes 
fluoxetine, sertraline, paroxetine, fluvoxamine, citalopram, 
and escitalopram. Binding almost exclusively to the serotonin 
transporter, these new antidepressants avoided many of 
the side effects commonly associated with the TCAs and 
MAOIs. Initially, it was not clear whether activity at a single 
monoamine transporter affected the efficacy of this class of 
medication, especially for the treatment of more severely ill 
patients. A meta-analysis that included 55 double-blind studies 
which compared an SSRI to nonselective agents (primarily 
tricyclics), found that SSRIs were slightly less effective than 
TCAs when given to inpatients, but in general, the two classes 
were approximately equal.26 A later meta-analysis also found 
that TCAs had greater efficacy with inpatients, and also 
confirmed the superior tolerability of SSRIs.27
Bupropion was introduced around the time of the SSRIs. 
Bupropion is unique, being the only antidepressant which 
selectively interacts with the norepinephrine and dopamine 
systems. Bupropion has not been extensively compared to 
TCAs. A number of small studies have found bupropion to 
be effective in patients who failed to respond to, or were 
unable to tolerate a TCA.28,29 The most widely cited study 
which compared bupropion to a TCA found that the TCA 
desipramine caused more treatment-emergent mood elevation 
in depressed bipolar patients when added to an ongoing 
therapeutic regimen of lithium or an anticonvulsant.
Venlafaxine was the first serotonin norepinephrine 
reuptake inhibitor (SNRI). Like many of the tricyclics, 
venlafaxine binds to the transporter protein of both 
norepinephrine and serotonin. Like the SSRIs, venlafaxine 
avoids side effects associated with antagonism of muscarinic 
cholinergic, H1-histaminic, and alpha-adrenergic receptors. 
More recently, duloxetine was introduced, which like 
venlafaxine and DVS is a SNRI.
Other antidepressants that interact with multiple 
monoamine systems include nefazodone, which is a weaker 
serotonin and norepinephrine reuptake inhibitor, but is a 
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potent serotonin 5-HT2 receptor antagonist. Nefazodone is 
rarely used currently due to the small possibility of hepatic 
injury, which could lead to the need for a liver transplant, 
or even death.30 Mirtazapine is a potent antagonist of central 
alpha-adrenergic autoreceptors, and heteroreceptors and is an 
antagonist of serotonin 5-HT2 and 5-HT3 receptors.
A comparison of the efficacy of the SSRIs and the newer 
dual-reuptake inhibitors is discussed in detail below in the 
context of evaluating the appropriate place in therapy of DVS.
New indications: pain
Antidepressants have received attention for the treatment 
of pain because it is believed that norepinephrine plays 
an important role in neuropathic pain. Neuropathic pain 
is non-nociceptive, therefore response to traditional analgesics 
such as opioids and nonsteroidal anti-inflammatory drugs is 
substantially reduced.31 TCAs, which like SNRIs block the 
reuptake of serotonin and norepinephrine, are considered 
first-line agents for most types of neuropathic pain.32 These 
agents work in both depressed and nondepressed patients, 
and the doses required for neuropathic pain are much smaller 
than antidepressant doses. Effects are often seen within a 
few days, as opposed to weeks needed for an antidepressant 
response.
It is thought that sensitization of neurons in the dorsal 
horn of the spinal cord can lead to chronic pain. Increased 
spontaneous activity of the dorsal horn neurons, a decreased 
threshold, and an increased responsivity to afferent input 
can cause hyperalgesia (increased sensitivity to pain) 
and allodynia (a painful response to a usually nonpainful 
stimulus). Inhibition of the reuptake of serotonin and 
norepinephrine within the dorsal horn appears to be the 
mechanism by which TCAs exert their analgesic effect.
Unfortunately, the adverse effect profile makes this class 
of drugs less than ideal, and the newer, better tolerated SNRIs 
are being studied for the treatment of pain. Duloxetine, for 
example, has been approved for the treatment of diabetic 
neuropathy and fibromyalgia. Venlafaxine, the precursor 
molecule of DVS, has been found to be effective at treating a 
number of painful conditions including pain associated with 
MDD,33 and a number of different neuropathic conditions.32 
A randomized study consisting of 40 patients with painful 
polyneuropathy found venlafaxine to be as effective as 
imipramine.34
Not all studies have supported the efficacy of SNRIs in the 
treatment of painful conditions. A recent meta-analysis of eight 
trials involving the SSRI paroxetine and the SNRI duloxetine 
failed to find an advantage for the dual action antidepressant.35 
Overall, both drugs were superior to placebo but the difference 
was small, of uncertain clinical significance, and may have been 
due to nonspecific effects related to improvement in mood.
DVS is also being studied for the treatment of pain. A pain 
scale was included as part of the large multicenter trials that 
established the efficacy of DVS in MDD. The scale used was 
the Visual Analog Scale – Pain Intensity (VAS-PI).36 The 
VAS-PI is a straight line, 100 mm in length, with the left end 
of the line representing no pain and the right end of the line 
representing the worst pain. Patients are asked to mark on 
the line where they think their pain is. The VAS-PI score is 
determined by measuring in millimeters from the left hand end 
of the line to the point that the patient marks. The assessment is 
highly subjective, and this scale is of most value when looking 
at change within individuals, and is of less value for comparing 
across a group of individuals at one time point.
Four randomized, double-blind, placebo-controlled trials 
found significantly greater decreases in the VAS-PI overall 
scores among subjects taking DVS compared to those taking 
placebo,9,14,37,38 and in a pooled analysis of two additional 
studies.39 Phase II/III studies are currently evaluating DVS 
in patients with fibromyalgia.
Although pain in not one of the criteria used by DSM-IV to 
establish a diagnosis of MDD, it is commonly experienced by 
depressed patients, and plays an important role in the functional 
impairment brought on by this disease. A cross-sectional study 
of data from a US national household survey conducted in 
1997–1998 identified 1,486 adults who met criteria for MDD 
or dysthymia.40 Chronic pain such as back pain, chronic 
headache, self-reported arthritis, or unspecified chronic pain 
was reported by 63% of this sample.
Depressed individuals in this study with comorbid pain 
reported more severe psychiatric distress than depressed 
persons who did not have pain, and had approximately 20% 
more visits to medical providers. Unfortunately, despite the 
increased medical utilization, the patients with comorbid pain 
were less likely to see a mental health specialist compared 
to patients without pain.
Individuals with pain, depression, or both who were 
enrolled in the Health and Retirement Study were evaluated 
to determine the impact on functioning of pain with unclear 
pathology. New onset of limitations in activities of daily 
living and work disability were seen with greater frequency 
among those who suffered from comorbid pain and depression 
compared to those with depression alone. Individuals who 
experienced depression plus pain were three to four times 
more likely to experience a new limitation in activities of 
daily living compared to those with depression alone.
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As the field of psychiatry moves from a primary focus on 
symptoms to a broader view of the patient which includes 
measures of functioning and quality of life, attention to 
pain syndromes associated with depression may become 
increasingly important.
Unmet needs
Despite the variety of treatment options, helping patients 
achieve full remission remains challenging. In the largest 
naturalistic study of depression, the Sequenced Treatment 
Alternatives to Relieve Depression (STAR*D) project, only 
about one-third of the participants reached remission after 
receiving the first level of treatment, which was citalopram 
as monotherapy.41 Those who did not become symptom-free 
were advanced to additional levels, however, remission rates 
were progressively lower in each subsequent treatment level: 
25% in level 2, and for those who did not achieve remission 
in level 2, 12% to 20% in level 3, and 10% in level 4. Over 
the course of all four treatment levels, almost 70% of those 
who did not withdraw from the study became symptom-free. 
However, the rate at which participants withdrew from the 
trial rose with each level: 21% withdrew after level 1, 30% 
after level 2, and 42% after level 3.
STAR*D used remission as an outcome measure, meaning 
that patients had to be essentially symptom-free. If response 
is used as an outcome measure, the success rate tends to be 
approximately 60%–70%. Response indicates that a patient 
has experienced a reduction in symptoms, and response is 
formally defined as a reduction in a depression rating scale 
score of at least 50%. One of the drawbacks of using response 
as a measure of success, however, is that residual symptoms 
of depression can cause substantial morbidity, and their 
presence is associated with a high risk of relapse.42
Tolerability can also be a problem with current 
antidepressant therapy. All newer antidepressants, with the 
exception of bupropion, carry the risk of inducing sexual side 
effects, which may, along with other troublesome side effects, 
contribute to early discontinuation of treatment.43 Adherence 
to medication can be particularly difficult during periods of 
normal mood when a medication is being used to prevent 
future episodes. Tolerability becomes increasingly important 
as the duration of medication use increases.
Another unmet need is for rapid onset of action. 
While some improvement is possible early in treatment, 
it generally takes weeks for an antidepressant to have its 
full effect.44 The reason for this delay is unknown. Although 
antidepressants cause an immediate increase in the activity 
of monoamine neurotransmitters, it is believed that chronic 
drug administration drives the production of adaptations in 
postreceptor signaling pathways, including regulation of 
neuronal gene expression, which is ultimately responsible 
for the therapeutic effects.45 A medication that bypassed the 
monoamine system, and directly targeted these downstream 
effects would be likely to have a more rapid onset of action.
In general, currently available antidepressants are 
effective medications. Nevertheless, there remains the need 
for new medications with higher remission rates, better 
tolerability, and a more rapid onset of action. Rather than 
being a revolutionary drug, DVS more modestly advances our 
ability to treat depression. DVS expands the limited options 
available to clinicians to target more than one neurotrans-
mitter, and it does it in a way that avoids interaction with 
post-synaptic receptors associated with the high side-effect 
burden of the previous generation of antidepressants.
Clinical evidence with desvenlafaxine
DVS was studied in phase II and III randomized placebo-
controlled trials that supported the US FDA indication for 
MDD.37–39,46–48 Phase II studies, although positive, were not 
published.
The first phase III study was an eight-week double-blind, 
placebo-controlled trial that included 480 adult outpatients 
with MDD. The change from baseline to endpoint in 
the 17-item Hamilton Rating Scale for Depression 
(HAM-D17) was used as the primary outcome measure 37 
(Table 4). Subjects were recruited from 25 centers throughout 
the United States. Secondary efficacy measures used were 
the Clinical Global Impressions-Improvement scale (CGI-I), 
Montgomery-Asberg Depression Rating Scale (MADRS), 
Clinical Global Impressions-Severity of Illness scale 
(CGI-S), rates of response (50% decrease of Ham-D17 
from baseline) and remission (HAMD-D17 score 7), and 
the VAS-PI overall score. Patients were randomly assigned 
at baseline to one of three fixed doses of DVS (100, 200, 
or 400 mg per day) or placebo. All patients who completed 
the study, regardless of treatment group, had the option of 
enrolling in a long-term, open-label extension study.
After eight weeks of treatment, the mean HAM-D17 
scores for DVS 100 mg per day (12.75) and 400 mg per day 
(12.50) were significantly lower than for placebo (15.31; 
p = 0.0038 and p = 0.0023, respectively); for DVS 200 mg 
per day, the mean score was 13.31 (p = 0.0764). CGI-I and 
MADRS results were significant for all groups; CGI-S results 
were significant with 100 mg per day and 400 mg per day. 
Response rates were significantly greater for DVS 100 mg per 
day (51%) and 400 mg per day (48%) versus placebo (35%; 
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p = 0.017 and p = 0.046, respectively); the response rate for 
DVS 200 mg per day was 45% (p = 0.142). Remission rates 
were significantly greater for DVS 400 mg per day (32%) 
versus placebo (19%; p = 0.035); remission rates were 30% 
for DVS 100 mg per day (p = 0.093) and 28% for DVS 
200 mg per day (p = 0.126).
Treatment with DVS was associated with improvement in 
some painful symptoms at the 100 mg dose, but for overall 
pain scores, neither the 200 mg nor the 400 mg dose group 
was statistically different from placebo. Greater attrition at 
higher doses early in the study may have made it difficult to 
measure dose response effects. Furthermore, most patients 
did not have a high level of pain at baseline, as pain was not 
an inclusion criterion for this study. Greater benefit may be 
observed with greater severity of pain at baseline.
The most commonly reported adverse events were 
nausea, insomnia, somnolence, dry mouth, dizziness, 
sweating, nervousness, anorexia, constipation, fatigue, and 
abnormal ejaculation/orgasm. Nausea occurred at the highest 
frequency (35%, 31%, and 41% in the DVS 100 mg, 200 mg, 
and 400 mg groups, respectively, compared with 8% in the 
placebo group). Among patients who discontinued due to 
adverse events, nausea was the most common adverse event 
cited as the reason for discontinuation.
Four patients had serious adverse events, including 
one death. One patient in the 100 mg group committed 
suicide on study day 5. It is not known whether this patient 
had taken any of the medication that was dispensed at the 
baseline visit. Three additional participants were reported 
to have had serious adverse events. One patient (400 mg) 
attempted suicide, another had a dystonic reaction from 
taking promethazine, and one patient in the placebo group 
experienced chest pain.
Mean increases in blood pressure in the DVS groups 
were statistically significant when compared with baseline 
and placebo at all weeks and the final on-therapy evaluation. 
None of the changes in vital signs were deemed to be of 
clinical significance. All DVS dosage groups had statistically 
significant decreases in weight when compared with baseline 
and placebo. One patient had clinically significant weight 
loss of greater than 7% of baseline body weight.
Statistically significant increases from baseline to end 
point were observed for the following laboratory values: 
alanine aminotransferase (ALT), aspartate aminotransferase 
Table 4 Desvenlafaxine compared to placebo and venlafaxine: adjusted mean change in HAMD17 from baseline in six 8-week randomized 
controlled trials
Level of evidence Once daily drug 
dose (mg) (n)
Adjusted mean 
change from baseline
p-value vs 
placebo
Reference
2 DvS 100 (114) -10.60 p = 0.0038 Demartinis et al37
DvS 200 (116) -9.63 p = 0.0764
DvS 400 (113) -10.74 p = 0.0023
Placebo (118) -7.65
2 DvS 200 (121) -12.6 p = 0.002 Septien-velez et al38
DvS 400 (124) -12.1 p = 0.008
Placebo (124) -9.3
2 DvS 100–200 (120) -9.6 p = 0.277 Liebowitz et al48
Placebo (114) -8.6
2 DvS 50 (158) -11.5 p = 0.018 Liebowitz et al47
DvS 100 (157) -11.0 p = 0.065
Placebo (159) -9.5
2 DvS 50 (145) -14.4 p  0.001 Boyer et al46
DvS 100 (126) -14.9 p  0.001
Placebo (138) -11.5
2 DvS 200–400 (226) -14.21 p  0.001 Lieberman et al39 
(pooled analysis)
vEN Er 75–150 (127) -14.26 p = 0.001
vEN Er 150–225 (115) -14.56 p  0.001
Placebo (245) -11.87
Abbreviations: DvS, desvenlafaxine; vEN Er, venlafaxine Er.
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(AST), gamma-glutamyl transferase (GGT), bilirubin 
alkaline phosphatase, fasting total cholesterol, and fasting 
triglycerides. In general, these changes were not clinically 
significant. Only four DVS-treated patients were determined 
to have clinically significant laboratory abnormalities.
Statistically significant increases from baseline in mean 
heart rate was observed for all DVS treatment groups 
when compared to placebo. Several small but statistically 
significant changes in electrocardiogram (ECG) intervals 
were observed, most of which were attributable to increases 
in heart rate (shortening of PR and QRS intervals).
Overall, in the first phase III study, DVS was found to 
have efficacy comparable to other antidepressant medications. 
Treatment with DVS was generally well tolerated, particularly 
at the 100 mg dose, with an adverse effect profile similar to 
other SNRIs. The rates of response (45%–51%) and remission 
(28%–32%) were consistent with those observed in other 
trials of short-term antidepressant treatment.49
The absence of a statistically significant difference 
between DVS 200 mg and placebo on the primary outcome 
measure is curious in light of the significant differences seen 
with the 100 mg and 400 mg doses. Considering that approxi-
mately half of clinical trials of antidepressants that ultimately 
receive approval fail to show a significant difference between 
active drug and placebo,50 this finding may be related to type II 
error rather than true lack of efficacy. Lack of separation 
seems to be particularly likely in fixed dose studies. In support 
of this interpretation, the DVS 200 mg group demonstrated 
statistically significant differences from placebo on the key 
secondary outcome measures (CGI-I, MADRS) as well as 
on measures of overall functioning.
A similar eight-week phase III randomized, double-blind, 
parallel group, placebo-controlled multicenter trial conducted 
in Europe (30 centers) and South Africa (5 centers) evaluated 
the 200 mg and 400 mg doses.38 As with the first study, the 
primary efficacy measure was change from baseline on the 
HAM-D17. Similar secondary measures were used as well. 
At the final on-therapy evaluation, adjusted mean change from 
baseline in the HAM-D17 total score was significantly greater 
with both DVS 200 mg per day (-12.6 ± 0.75; p = 0.002) and 
DVS 400 mg per day (-12.1 ± 0.74; p = 0.008), compared 
with placebo (-9.3 ± 0.74). A significant difference in total 
score vs. placebo was observed starting at week 4 for both 
DVS 200 mg per day (p  0.004) and DVS 400 mg per day 
(p  0.049), and were sustained until the end of the study.
Both doses of DVS also performed well on the secondary 
measures. Response rates were 60%, 56%, and 38% 
for DVS 200 mg per day, 400 mg per day and placebo, 
respectively. Significantly more participants treated with 
DVS 200 mg per day achieved remission compared with 
placebo (37% vs 23%, respectively; p = 0.017). Although 
not statistically significant, remission rates on the HAM-D17 
were numerically higher for DVS 400 mg per day than for 
placebo (34% vs 23%, respectively; p = 0.066).
Treatment-emergent adverse events were reported by 
70% of placebo participants, 85% of DVS 200 mg per day 
participants and 90% of DVS 400 mg per day participants. 
The adverse events reported were similar to the first study. 
An analysis of change over time found that the side effects 
tended to resolve as participants continued to take the 
medication. The incidence of the most common treatment-
emergent adverse events (nausea, dry mouth, sweating, 
dizziness, fatigue, and constipation) was highest during the 
first week of treatment and decreased rapidly so that from 
week three onward no major differences were observed 
between the DVS and placebo treatment groups.
DVS 400 mg per day was associated with small but 
significant increases from baseline in mean pulse rate and 
diastolic blood pressure; a significant decrease from baseline 
in mean body weight was observed for participants in both 
DVS groups.
Statistically significant changes were seen in the 400 mg 
group in the following laboratory studies: ALT, AST, GGT, 
bilirubin, alkaline phosphatase and fasting high-density 
lipoprotein (HDL) cholesterol. Only the differences in bilirubin 
(decrease) and alkaline phosphatase (increase) were statistically 
significant in the 200 mg group. None of the laboratory changes 
were associated with clinical symptoms, and all were reversed 
when DVS treatment was discontinued.
As seen in the first study, several small but statistically 
significant ECG changes were observed in both DVS 
treatment groups. As before, these changes were attributable 
to increases in mean heart rate, and were not clinically 
significant.
The third phase III trial failed to separate from placebo on 
the primary outcome measure.48 This study utilized a 100 mg 
per day starting dose, with an increase to 200 mg per day at 
two weeks. The dose could be decreased back to 100 mg for 
safety or tolerability reasons. It was an eight-week multicenter 
double-blind randomized trial involving 247 outpatients, and 
used the same primary and secondary efficacy measures as 
the two previous trials. Following the initial titration period 
(days 1–14) the mean daily dose of DVS for the intent-to-treat 
population was 179.0 to 195.3 mg. For those who completed 
the entire eight-week trial, the mean daily dose was 182.4 
to 195.2 mg.
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At this point the weight of evidence supported the 
efficacy and safety of DVS, and substantial advantages of 
higher doses over lower doses had not been seen. The next 
study that was undertaken attempted to better establish the 
minimum effective dose in a three arm study consisting of 
DVS 100 mg, DVS 50 mg, and placebo.47 This multi-center, 
double-blind study enrolled 447 outpatients who were treated 
for eight weeks. The inclusion and exclusion criteria, and 
primary and secondary efficacy measures were the same as 
in the previous trials.
DVS 50 mg per day was associated with a significantly 
greater mean change from baseline on the HAM-D17 
(-11.5) compared to placebo (-9.5; p = 0.018); the 100 mg 
dose group (-11.0) did not achieve statistical significance 
(p = 0.065). The 100 mg group did, however, demonstrate 
significant improvements compared with placebo on several 
secondary efficacy measures, including the 6-item Hamilton 
Depression Rating Scale and the VAS-PI total score.
An important addition to this study was the inclusion 
of the Discontinuation-Emergent Signs and Symptoms 
(DESS) checklist, which was used to evaluate adverse 
events that occurred or worsened during and after the 
seven-day taper period when the medication was discontinued. 
Discontinuation-related symptoms are common with many 
antidepressants,51 and may be more common with SNRIs.52 
In this study, however, the DESS score for both DVS doses 
appeared to be comparable or lower than DESS scores 
reported in published studies for other SNRIs and SSRIs.53,54 
Additionally, neither the tapered DVS 100 mg per day group, 
nor the group discontinued from DVS 50 mg per day without 
a taper, had a mean change in DESS score of greater than 
three points, the threshold defined as a “discontinuation 
syndrome”.54
Both DVS doses were generally well tolerated. Of note, 
nausea, which was the most frequently reported adverse 
event in previous studies, was not among the most commonly 
reported in this study. Moreover, the rate of nausea associated 
with DVS during the first week of treatment (at a dose of 
50 mg per day) was substantially lower compared with those 
in a previous study (22%–31%) in which DVS treatment 
was initiated at 100 mg per day.37 Rates of discontinuation 
(3%–7%) due to adverse events in this study were also 
lower than in the previous studies which used higher doses 
(11%–21%). Withdrawals due to adverse events were evenly 
distributed throughout the treatment period, whereas previous 
studies, in which treatment was initiated at doses of 100 mg 
per day or higher, most discontinuation events occurred 
during the first two weeks of treatment.
The lower dose strategy was tested in a similar study of 
483 subjects conducted in multiple centers throughout Europe 
and South Africa.46 Both doses were superior to placebo 
across all primary and secondary efficacy measures. As in 
the previous study, the efficacy of the 50 mg and 100 mg 
doses was comparable to that observed at higher doses,37,38 
and adverse events were similar to those reported with other 
SNRIs.55 As expected, fewer adverse events were reported 
compared to studies which used higher doses.
The two 50 mg per day studies found this dose to be 
effective and well tolerated even without initial titration. 
Additionally, this dose was associated with minimal side 
effects upon discontinuation without a taper. A question that 
arises from these results is whether an even smaller dose 
would also be effective. Ideally, dose-finding studies test 
progressively lower doses until an inactive dose is identified, 
thereby establishing a minimum floor. Thus far 50 mg is the 
lowest dose tested in a published study.
Two similarly designed studies compared DVS to 
placebo using venlafaxine ER as an active control. Although 
individually neither demonstrated statistically significant 
differences on the primary outcome measure, a pooled 
analysis supported the superiority of DVS compared to 
placebo.39 One of the studies was done in the United States, 
and the other in Europe. Both had a high placebo response 
rate, and in retrospect it appeared that they had not been 
adequately powered to detect a difference in the setting 
of this high placebo response rate. The similarities of the 
protocols allowed the results were to be pooled in order to 
increase the number of subjects in the analysis, and provide 
adequate statistical power.
A total of 738 patients were randomly assigned to 
eight weeks of treatment with placebo (250 patients), DVS 
(239 patients), or venlafaxine ER (249 patients). The initial 
target dose of DVS was 200 mg per day with the option to 
increase to 400 mg per day after study day 28. In the European 
study venlafaxine ER was dosed between 75 mg per day and 
150 mg per day, while in the US study the allowable range was 
75 mg per day to 225 mg per day. Because of this difference in 
dosing guidelines, the venlafaxine ER data was not pooled.
The primary outcome measure was change from baseline 
in the 17-item Hamilton Rating Scale for Depression 
(HAM-D17). A statistically significant difference between 
DVS and placebo was observed at week three, and maintained 
throughout the treatment period. There were no significant 
differences between DVS and venlafaxine ER, however the 
study was not designed to identify differences between these 
two groups.
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A number of secondary measures were also found to 
be statistically significant, including the CGI-S, and the 
visual analog scale for back pain, chest pain, arm/leg/joint 
pain, and overall pain. Clinical Global Impression Scale – 
Improvement (CGI-I) and improvement in stomach pain were 
not statistically different from placebo. Adverse effects were 
those typically seen in other studies, and included nausea, 
somnolence, dry mouth, and sweating.
The high placebo response rate observed in the two studies 
reflects the increasing placebo response rate observed in 
many studies over recent years. A review of controlled trials 
published in English between January 1981 and December 
2000 in which adult outpatients with MDD were randomly 
assigned to receive medication or placebo found that the 
placebo response rate has increased by approximately 7% per 
decade.56 Variability was large ranging from approximately 
10% to more than 50%. The placebo response rate in the 
pooled DVS analysis was 47%.
In summary, desvenlafaxine at the 50 mg dose has been 
shown to be superior to placebo in treating MDD. While 
doses as high as 400 mg per day have been tested, there is 
no evidence that doses higher than 50 mg/day are more 
effective. In some studies, higher doses did not separate 
from placebo, whereas lower doses did.37,48 The reason for 
this difference is unclear. A consistent finding, however, is 
the greater incidence of adverse events at higher doses; the 
50 mg dose was the best tolerated. All of the phase III studies 
using desvenlafaxine for depression have been short term 
(eight weeks). Long term placebo-controlled maintenance 
data is not yet available.
With respect to safety and tolerability, the most 
commonly observed side effects of desvenlafaxine were 
nausea, dry mouth, somnolence, sweating, constipation 
and decreased appetite, resulting in statistically significant 
weight loss ranging from 0.18 to 1.82 kg over the course of 
eight weeks.
Cardiovascular side effects were observed which were 
small, yet statistically significant. Increases in supine pulse 
rate ranged from 0.69 to 5.79 beats per minute. Increases 
in systolic blood pressure ranged from 0.61 to 4.05 mmHg. 
Mean increases in diastolic blood pressure ranged from 
0.66 to 3.41 mmHg. Mean increases in QTc ranged from 
0.18 to 7.25 milliseconds. It should be noted that individual 
patients may experience larger changes, and while it does not 
appear to be necessary to monitor the ECG, blood pressure 
should be monitored, as with the other SNRIs.
There were a number of laboratory findings associated with 
desvenlafaxine treatment. Statistically significant increases 
were observed in alkaline phosphatase (1.1–8.9 U/L), GGT 
(1.3–11.0 U/L), AST (1.6–2.9 U/L), ALT (3.9–4.2 U/L), total 
cholesterol (0.10–0.23 mmol/L), HDL (0.035–0.060 mmol/L), 
low-density lipoproteins (LDL; 0.05–0.17 mmol/L), and 
triglycerides (0.11–0.13 mmol/L). Statistically significant 
decreases were observed in total bilirubin ranging 
from 0.6 to 2.2 mg/dL. While these test changes were not 
associated with clinical findings, laboratory monitoring for 
individuals undergoing treatment with desvenlafaxine may 
be indicated for individuals with pre-existing liver or lipid 
abnormalities.
Although there were no observations of desvenlafaxine 
causing suicidality, like all antidepressants, desvenlafaxine 
carries the required FDA black box warning on suicidality. 
Good clinical practice requires close monitoring of any 
patient treated with antidepressants for emerging suicidality, 
particularly in severely depressed patients initiating 
therapy.
Economic evidence
Due to the high prevalence of MDD, the availability of 
effective, well tolerated antidepressants, and the diminishing 
stigma of receiving treatment, medical costs associated 
with MDD constitute a significant portion of health 
care expenditures. The need for information on the cost 
effectiveness of interventions for depression is being driven 
by rising costs and the scarcity of mental health resources.
Economic evaluations aim to combine costs and patient 
outcomes in one analysis. Outcome measures may include 
the cost per success (for example remission), cost per 
symptom-free day, or total cost, both inpatient and outpatient, 
over a specified period of time. Although the focus is often 
on the cost of the antidepressant drug itself, in actuality, 
drug costs represent only 10% of the overall economic 
costs of depression.57 Consequently, other factors, such as 
hospitalization, physician costs, and indirect costs associated 
with lost productivity must be included in a comprehensive 
analysis.
Because DVS was introduced only recently, studies 
involving economic analyses have not yet been performed. 
Indirect evidence, involving the evaluation of venlafaxine, 
the parent compound of DVS, suggests that DVS has the 
potential to be a cost-effective option in the treatment of 
MDD. Venlafaxine has been compared to both generic SSRIs 
and the older tricyclic antidepressants, and in most studies has 
been shown to be the more cost effective agent.21,58–63 This is 
largely driven by the small, though statistically significant 
advantage that the SNRIs have in bringing about response 
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and remission which result in savings that outweigh the 
higher acquisition costs.64 One study concluded that that the 
cost of an SSRI could be reduced to a few pennies per day, 
and the cost of a tricyclic to zero before the overall cost of 
venlafaxine treatment ceased to be lowest.60
Some studies found escitalopram, which also has higher 
acquisition costs than the generic SSRIs, to be more cost 
effective than venlafaxine,65–67 although others did not,61,68,69 
making this finding less consistent.
The inclusion of the cost of treating medical comorbities 
in the analysis appears to be important. Some analyses 
found that there was no cost advantage to treatment with 
venlafaxine compared to SSRIs until the medical costs of 
nonpsychiatric care was included in the analysis.62,63 This 
finding may reflect the efficacy of venlafaxine and other 
SNRIs in the treatment of pain that is frequently seen in 
patients with MDD.
Looking beyond the cost of the antidepressant itself, 
agents with a dual mechanism of action are associated 
with higher rates of remission, more depression free days, 
and reduced pain-symptom morbidity, which can lead to 
reduced health service utilization. An important caveat is 
that the evidence reviewed involved venlafaxine rather 
than DVS. Although DVS has the theoretical advantage of 
noradrenergic activity at typical starting doses, whether DVS 
will show cost advantages similar to venlafaxine remains 
to be seen, particularly in the setting of the availability of 
generic venlafaxine.
Dosage and administration
Desvenlafaxine is available as an ER tablet in the form 
of desvenlafaxine succinate, a stable salt, which results in 
bioavailablility of 80% when taken orally. Each tablet contains 
76 mg or 152 mg of desvenlafaxine succinate, equivalent to 
50 mg or 100 mg of desvenlafaxine.70 The recommended 
starting and maintenance dose of desvenlafaxine is a 50 mg 
ER tablet taken orally once daily with or without food. Based 
on published data, there is no clinical evidence that doses 
greater than 50 mg per day confer any additional benefit for 
treatment of MDD,47 and higher doses may be associated with 
greater incidence of adverse events, especially nausea.37,38,48 
However, some patients may require a higher dose, and 
Pristiq® is available in both 50 mg and 100 mg. Doses as high 
as 400 mg per day have been shown to be effective. There 
is also some evidence that higher doses are more effective 
for pain symptoms.38
Because Pristiq® tablets have an ER formulation, the 
tablet can not be divided, crushed or chewed; thus titration 
in increments of less than 50 mg has to be done on an every 
other day basis. Discontinuation of a 50 mg per day dose 
without a taper was not associated with a discontinuation 
syndrome,47 however, gradual dose reduction from higher 
doses is recommended.
Place in therapy
SNRIs, SSRIs, and the other newer antidepressants are 
all considered first line treatments for MDD. No single 
antidepressant works best for all patients, and some patients 
may need to try numerous medications before they find 
one that is both effective and tolerable. Consequently, it is 
important to have a broad range of options available.
It is generally believed that all antidepressants approved 
by the US FDA are similarly effective.71 However, because 
SNRIs block the reuptake of both norepinephrine and 
serotonin there has been some interest in whether they may 
have greater efficacy than the SSRIs which only block the 
reuptake of serotonin. Because DVS has been available 
for only a short period of time, head-to-head comparisons 
with other SSRIs have not yet been performed. A number 
of studies have been published comparing venlafaxine to 
SSRIs, however, and these have tended to favor the SNRI, 
but only by small margins.
A metaanalysis combined data from 34 studies comparing 
venlafaxine to fluoxetine (n = 20), paroxetine (n = 8), 
sertraline (n = 3), citalopram (n = 2), and fluvoxamine (n = 1). 
The primary outcome measure was remission following eight 
weeks of treatment. The differences numerically favored 
venlafaxine over SSRIs in 28 studies, with six studies 
numerically favoring the SSRI over venlafaxine. Overall, 
venlafaxine therapy was associated with a statistically 
significant 5.9% (95% confidence interval [CI]: 0.038–0.081) 
advantage.72
Tolerability was similar for the two classes of medication. 
Overall discontinuation rates for any reason were 28% for the 
pooled venlafaxine and 27% for the pooled SSRI treatment 
groups. A higher percentage (11%) of venlafaxine-treated 
patients discontinued therapy because of adverse events 
compared with SSRIs (9%; p = 0.0011). Discontinuation 
rates because of lack of efficacy were 4% for venlafaxine 
and 5% for SSRIs.
A similar study that looked at response rather than 
remission also found a modest advantage for the dual 
action agents.73 This metaanalysis, which included 93 trials 
with 17,036 subjects, used a broad definition of dual action 
antidepressant, which included dual reuptake inhibitors, and 
drugs that affected both the serotonin and norepinephrine 
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systems in other ways. The specific drugs included were 
venlafaxine, duloxetine, milnacipran, mirtazapine, mianserin, 
and moclobemide.
The average response rate of the dual action antidepressants 
was 63.6% compared to 59.3% for the SSRIs. The number 
needed to treat was 24, indicating that 24 patients would 
need to be treated with dual-action antidepressant drugs 
instead of SSRIs in order to obtain one additional responder. 
This number may have underestimated the true comparative 
advantage of SNRIs due to the broad inclusion of non-SNRI 
medications.
If a patient demonstrates treatment resistance by failing 
to respond to a trial of antidepressant therapy, guidance 
on selecting the next most appropriate step is sparse. 
Unfortunately, failure to respond to an antidepressant is 
common. As noted above, in the STAR*D trial, only about 
30% of patients were in remission following up to 12 weeks 
of therapy with the SSRI citalopram.41
If a patient continues to experience depressive symptoms, 
despite an optimal antidepressant trial, two general strategies 
exist. The first involves augmentation with a second 
medication, and the other involves discontinuing the first 
antidepressant, and switching to a second.74 Augmentation 
requires a patient to take two medications, while switching 
maintains treatment with a single one. The latter, more simple 
medication regimen may have advantages with regard to 
adherence and minimization of side effects.
For patients who are initially given an SSRI antidepressant, 
switch options include a within-class switch to a second 
SSRI, or an across-class switch to a medication with a 
different mechanism of action. Few studies have been 
carried out comparing within class to across class switches. 
The largest study was done as part of the STAR*D study 
in which patients who did not experience remission after 
14 weeks of citalopram were randomized to a second SSRI 
(sertraline), bupropion (a medication with norepinephrine 
and dopamine activity), or venlafaxine.75 A total of 727 
subjects were enrolled in this study, and no statistically 
significant differences were found among the three study 
arms. Remission rates were: sertraline, 17.6%; bupropion, 
21.3%; and venlafaxine, 24.8%.
The STAR*D study was powered to detect a 15% 
between-group difference in remission rates. In order to 
increase the power of the statistical analysis, and detect 
smaller, yet potentially meaningful differences between the 
two switch strategies, Papakostas and colleagues performed 
a meta-analysis of data from four clinical trials, which 
included 1,496 subjects. Subjects in these studies who did not 
experience remission on various SSRIs were randomized to 
receive a second SSRI (paroxetine, sertraline, or citalopram) 
or a non-SSRI antidepressant (venlafaxine, mirtazapine, or 
bupropion). Patients who received an across-class switch 
were significantly more likely to experience remission than 
those who had a within-class switch (pooled risk ratio for 
remission 1.29; p = 0.007). The number needed to treat in 
this analysis was 22.
DVS was not available when these comparative studies 
were undertaken. Although one may hypothesize that its 
performance would be similar to the parent compound 
venlafaxine, it remains to be established in clinical trials. 
An advantage that DVS may have is that it is more equal 
in its effect on serotonin and norepinephrine compared to 
venlafaxine. Venlafaxine does not have an appreciable effect 
on the norepinephrine system until it is titrated to approximately 
225 to 375 mg per day.76 Doses of this magnitude are 
frequently used in clinical trials, but doses below 100 mg 
are more typical in routine practice.43 Consequently, many 
patients receiving venlafaxine in a non-research environment 
are essentially experiencing an SSRI effect. Because DVS 
blocks the reuptake of both serotonin and norepinephrine at 
starting doses, patients in real world settings may experience 
dual reuptake inhibition with greater consistency.
Given the brief duration of DVS availability, its ultimate 
place in therapy will become more clear over time. As a new 
SNRI, it may prove to be a valuable addition to available 
antidepressant medications. The clinical superiority of the 
dual action antidepressants over many of the SSRIs is a well 
replicated finding, but the effect size is small. Perhaps more 
important is the potential for economic advantages over 
older agents, and efficacy in the treatment of pain. Comorbid 
pain appears to be common among patients suffering from 
depression, but despite the serious functional impairment 
it can cause, it has received little attention until recently. 
Like duloxetine, treatment with DVS was associated with 
statistically significant reductions in most pain scales that 
were used in the registrational trials. SSRIs have not been 
found to be particularly effective in treating pain, but 
additional head-to-head comparisons between SSRIs and 
SNRIs are needed before firm conclusions can be drawn.
Among the newer antidepressants, only duloxetine and 
DVS block the reuptake of both serotonin and norepinephrine 
at starting doses. Because only a minority of patients 
experience remission after an initial trial of an antidepressant, 
and because it is not possible to know in advance which 
antidepressant will help a particular patient, a greater number 
of options can lead to better results. As one of only a limited 
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number of SNRIs, DVS has the potential to play a significant 
role in improving treatment outcomes.
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